Chinese Clinical Oncology

• 论著 • Previous Articles     Next Articles

Clinical observation of pemetrexed combined with carboplatin for anthracycline and taxaneresistant advanced metastatic breast cancer

LI Ya-li,ZHOU Heng-gen,NI Jing-zhong,LIU Lan-fang,CHENG Yan,LI Hua-nian.   

  1. Department of Oncology, the Peoples Hospital of Pizhou City
  • Received:2012-07-17 Revised:2012-09-26 Online:2012-12-31 Published:2012-12-31

Abstract:

Objective To observe the efficacy and toxicity of the combination of pemetrexed and carboplatin in the treatment of anthracycline and taxaneresistant advanced metastatic breast cancer(MBC) patients.
Methods Thirtyone patients with advanced MBC failed to previous chemotherapy with anthracycline and taxane were enrolled in the study from March 2010 to January 2012. The patients
received pemetrexed(500mg/m2 iv, d1) and carboplatin(AUC=5 iv,d2) with 21 days as a cycle. Each patient received at least two cycles. Results Of the 31 patients, no patient got CR, 12 got PR, 10 cases had SD,9 cases had PD, response rate was 387%(12/31) and the disease control rate was 71.0%(22/31). The improvement rate of KPS score was 67.7%(21/31). The median time to progress was 6.0(3-14) months, the median overall survival was 8.3(4-18) months. The main toxic reactions were myelosuppression, digestive tract reaction, fatigue and rashes, mainly in grade 1-2.
Conclusion The combination of pemetrexed and carboplatin is effective for advanced MBC failed to anthracyclines and taxanes with tolerant toxicity, and worth further study.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!